Screener
Bristol-Myers Squibb BMY Cobenfy — Total Revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Bristol-Myers Squibb in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The source filing: Bristol-Myers Squibb’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 11:10 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000014272-26-000020
| Dollars in millions | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Zeposia | 169 | 150 | 287 | 257 |
| Sotyktu | 87 | 70 | 156 | 126 |
| Krazati | 55 | 48 | 105 | 96 |
| Cobenfy | 63 | 35 | 119 | 62 |
| Other Growth products(a) | 653 | 557 | 1,234 | 1,063 |
| Total Growth Portfolio | 7,560 | 6,596 | 13,787 | 12,159 |
| Legacy Portfolio | ||||
| Eliquis | 4,481 | 3,680 | 8,617 | 7,245 |
Item 1. FINANCIAL STATEMENTS
FAQ
- What is Bristol-Myers Squibb's cobenfy — total revenues?
- Bristol-Myers Squibb (BMY) reported cobenfy — total revenues of $63M in Q2 2026.
- How has Bristol-Myers Squibb's cobenfy — total revenues changed year-over-year?
- Bristol-Myers Squibb's cobenfy — total revenues increased by 80.0% year-over-year, from $35M to $63M.
- What does cobenfy — total revenues mean?
- This metric represents the total net sales generated from the Cobenfy product line, a novel therapeutic treatment within the company's neuroscience portfolio. It captures the commercial performance and market adoption of this specific asset, reflecting its contribution to the firm's overall revenue growth and therapeutic diversification. As a key growth driver, this revenue stream is critical for evaluating the successful commercialization of new drug launches.
Ask your AI about Bristol-Myers Squibb's cobenfy — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude